Novavax to Highlight RSV Program Data at Two Upcoming Meetings
October 02 2018 - 04:05PM
Novavax to Highlight RSV Program Data at Two Upcoming Meetings
Novavax, Inc. (NASDAQ: NVAX) today announced that its
representatives will share data from its RSV F vaccine program via
oral and poster presentations at IDWeek 2018 in San Francisco,
California, taking place October 3-7 and at the 11th International
Respiratory Syncytial Virus Symposium in Asheville, North Carolina,
taking place October 31-November 4.
Oral presentation details are as
follows:
IDWeek 2018
Meeting |
|
|
|
Title: |
|
Progress Toward a Vaccine for
Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV)
Lower Respiratory Tract Illness (LRTI) in Infants |
Presenter: |
|
Louis F. Fries III, M.D., Senior
Vice President and Chief Medical Officer, Novavax, Inc. |
Session: |
|
213. Late Breaker Oral Abstracts:
Influenza and Vaccines |
Date and Time: |
|
Saturday, October 6, 11:20 a.m.
P.T. |
Location: |
|
Moscone Convention Center S
152-154 |
|
|
|
11th
International Respiratory Syncytial Virus Symposium |
|
|
|
Title: |
|
Magnitude and Durability of
Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One
Year Following Immunization with RSV F Nanoparticle Vaccine
Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant |
Presenter: |
|
Vivek Shinde, M.D., M.P.H.,
Executive Director, Clinical Development, Novavax, Inc. |
Session: |
|
5. Advancements in RSV
Vaccines |
Date and
Time: |
|
Thursday, November 1, 4:45 p.m. –
6:15 p.m. E.T. |
Location: |
|
Omni Grove Park Inn |
|
|
|
Title: |
|
Progress Toward a Vaccine for
Maternal Immunization to Prevent Respiratory Syncytial Virus Lower
Respiratory Tract Illness (RSV LRTI) in Infants |
Presenter: |
|
Louis F. Fries III, M.D., Senior
Vice President and Chief Medical Officer, Novavax, Inc. |
Session: |
|
12. Maternal Immunity &
Maternal Vaccination |
Date: |
|
Saturday, November 3, 3:00 p.m. –
4:30 p.m. E.T. |
Location: |
|
Omni Grove Park Inn |
|
|
|
Poster presentations for the 11th International
Respiratory Syncytial Virus Symposium will occur on Thursday,
November 1, 11:30 a.m. – 12:30 p.m. E.T. and on Friday, November 2,
8:30 p.m. – 10:00 p.m. E.T. at the Omni Grove Park Inn.
Title: |
|
Feasibility Evaluation of Blow
Fill Seal Process and Compatibility with Aluminum Phosphate
Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal
Immunization |
Presenter: |
|
Yen-Huei Lin, Ph.D., Senior
Director, Formulation and Drug Product Development, Novavax,
Inc. |
|
|
|
Title: |
|
Binding Kinetics of RSVF
Prefusogenic Vaccine to Palivizumab and Serum Polyclonal
Antibody |
Presenter: |
|
Hanxin Lu, Ph.D., Principal
Scientist, Novavax, Inc. |
|
|
|
Title: |
|
In-depth Analytical
Characterization and Structural Modeling of Novavax RSV F
Nanoparticle Vaccine |
Presenter: |
|
Ernest Maynard, Ph.D., Principal
Scientist, Analystical Development, Novavax, Inc. |
|
|
|
Title: |
|
Antigenic Characterization
Prefusogenic Nanoparticle Vaccine, Prefusion, and Postfusion F
against a Broad Range of Neutralizing Monoclonal Antibodies and
Epitope Responses in Cotton Rats |
Presenter: |
|
Nita Patel, Director, Antibody
Discovery, Vaccine Development Novavax, Inc. |
|
|
|
Title: |
|
Respiratory Syncytial Virus (RSV)
Prefusogenic F Nanoparticle Vaccine Compared to Prefusion and
Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity,
and Protection |
Presenter: |
|
Gale Smith, Ph.D., Vice
President, Vaccine Development, Novavax, Inc. |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage
biotechnology company that drives improved health globally through
the discovery and development of innovative vaccines to prevent
serious respiratory diseases. ResVax™, its RSV vaccine for infants
via maternal immunization, is the only vaccine in a Phase 3
clinical program and is poised to help prevent the second leading
cause of death in children under one year of age worldwide. Novavax
is also advancing NanoFlu™, its quadrivalent influenza nanoparticle
vaccine, to address key factors that can lead to the poor
effectiveness of currently approved flu vaccines. Novavax is a
leading innovator of recombinant vaccines; its proprietary
recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce a new class of highly
immunogenic nanoparticles addressing urgent global health
needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:
InvestorsNovavax, Inc.Erika TrahanSenior Manager, Investor &
Public Relationsir@novavax.com240-268-2000
Westwicke PartnersJohn
Woolfordjohn.woolford@westwicke.com443-213-0506
MediaSam BrownMike Beyermikebeyer@sambrown.com312-961-2502
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024